Claims for Patent: 5,516,896

Summary for Patent: 5,516,896

Title:	Biologically active B-chain homodimers
Abstract:	Dimeric proteins having substantially the same biological activity as PDGF are disclosed. More specifically, the protein may have two substantially identical polypeptide chains, each of the chains being substantially homologous to the B-chain of PDGF. Alternatively, the protein may have two polypeptide chains that are substantially identical to the B-chain of PDGF. In addition, proteins comprising polypeptides that are variants or derivatives of the B-chain of PDGF are also disclosed. Therapeutic compositions containing these proteins and methods for enhancing the wound-healing process in warm-blooded animals are also disclosed.
Inventor(s):	Murray; Mark J. (Seattle, WA), Kelly; James D. (Seattle, WA)
Assignee:	ZymoGenetics, Inc. (Seattle, WA)
Application Number:	07/381,096
Patent Claims:	1. A protein having two PDGF-B polypeptide chains, said chains having one or more of the following modifications: (a) one or more amino acid substitutions of cysteine residues corresponding to residues 43, 49, 52, and 53 of the PDGF B chain; (b) a deletion of 1 to 14 amino acids at the N-terminus of the protein; and (c) a deletion of 1 to 9 amino acids at the C-terminus of the protein. 2. The protein of claim 1 wherein the cysteine residue corresponding to residue 43 is changed to serine. 3. The protein of claim 1 wherein the cysteine residue corresponding to residue 52 is changed to serine. 4. The protein of claim 1 wherein the cysteine residue corresponding to residue 53 is changed to serine. 5. The protein of claim 1 wherein said polypeptide chains comprise the B-chain of PDGF from amino acid 15 to amino acid 109, optionally having one or more amino acid substitutions of cysteine residues corresponding to residues 43, 49, 52, and 53 of the PDGF B chain. 6. The protein of claim 1 wherein said polypeptide chains comprise the B-chain of PDGF from amino acid 15 to amino acid 101, optionally having one or more amino acid substitutions of cysteine residues corresponding to residues 43, 49, 52, and 53 of the PDGF B chain. 7. The protein of claim 1 wherein said polypeptide chains comprise the B-chain of PDGF from amino acid 1 to amino acid 101, optionally having one or more amino acid substitutions of cysteine residues corresponding to residues 43, 49, 52, and 53 of the PDGF B chain. 8. The protein according to claim 5, 6, or 7, further comprising one or more amino acid substitutions of cysteine residues corresponding to residues 43, 49, 52, and 53 of the PDGF B chain. 9. A therapeutic composition comprising a protein having two PDGF-B polypeptide chains, said chains having one or more of the following modifications: (a) one or more amino acid substitutions of cysteine residues corresponding to residues 43, 49, 52, and 53 of the PDGF B chain; (b) a deletion of 1 to 14 amino acids at the N-terminus of the protein; and (c) a deletion of 1 to 9 amino acids at the C-terminus of the protein, said protein being chemotactic or mitogenic for fibroblasts, and a physiologically acceptable carrier or diluent. 10. The therapeutic composition of claim 9 wherein the cysteine residue corresponding to residue 43 is changed to serine. 11. The therapeutic composition of claim 9 wherein the cysteine residue corresponding to residue 52 is changed to serine. 12. The therapeutic composition of claim 9 wherein the cysteine residue corresponding to residue 53 is changed to serine. 13. The therapeutic composition of claim 9 wherein said polypeptide chains comprise the B-chain of PDGF from amino acid 15 to amino acid 109, optionally having one or more amino acid substitutions of cysteine residues corresponding to residues 43, 49, 52, and 53 of the PDGF B chain. 14. The therapeutic composition of claim 9 wherein said polypeptide chains comprise the B-chain of PDGF from amino acid 15 to amino acid 101, optionally having one or more amino acid substitutions of cysteine residues corresponding to residues 43, 49, 52, and 53 of the PDGF B chain. 15. The therapeutic composition of claim 9 wherein polypeptide chains comprise the B-chain of PDGF from amino acid 1 to amino acid 101, optionally having one or more amino acid substitutions of cysteine residues corresponding to residues 43, 49, 52, and 53 of the PDGF B chain. 16. The therapeutic composition according to claim 13, 14, or 15, further comprising one or more amino acid substitutions of cysteine residues corresponding to residues 43, 49, 52, and 53 of the PDGF B chain. 17. The therapeutic composition of claim 9 wherein said protein is present in a concentration of from about 1 to 50 micrograms per milliliter of total volume. 18. The therapeutic composition of claim 9 wherein said carrier or diluent is selected from the group consisting of albumin, sterile water, and saline. 19. The therapeutic composition of claim 18, including an adjuvant. 20. The therapeutic composition of claim 19 wherein said adjuvant is selected from the group consisting of collagen, hyaluronic acid, fibronectin, factor XIII, and an antibiotic. 21. A method for enhancing the wound-healing process in warm-blooded animals, comprising administering to the animal a therapeutically effective amount of a protein having two PDGF-B polypeptide chains, said chains having one or more of the following modifications: (a) one or more amino acid substitutions of cysteine residues corresponding to residues 43, 49, 52, and 53 of the PDGF B chain; (b) a deletion of 1 to 14 amino acids at the N-terminus of the protein; and (c) a deletion of 1 to 9 amino acids at the C-terminus of the protein, said protein being chemotactic and mitogenic for fibroblasts, and a physiologically acceptable carrier or diluent. 22. The method of claim 21 wherein the cysteine residue corresponding to residue 43 is changed to serine. 23. The method of claim 21 wherein the cysteine residue corresponding to residue 52 is changed to serine. 24. The method of claim 21 wherein the cysteine residue corresponding to residue 53 is changed to serine. 25. The method of claim 21 wherein said polypeptide chains comprise the B-chain of PDGF from amino acid 15 to amino acid 109, optionally having one or more amino acid substitutions of cysteine residues corresponding to residues 43, 49, 52, and 53 of the PDGF B chain. 26. The method of claim 21 wherein said polypeptide chains comprise the B-chain of PDGF from amino acid 15 to amino acid 101, optionally having one or more amino acid substitutions of cysteine residues corresponding to residues 43, 49, 52, and 53 of the PDGF B chain. 27. The method of claim 21 wherein said polypeptide chains comprise the B-chain of PDGF from amino acid 1 to amino acid 101, optionally having one or more amino acid substitutions of cysteine residues corresponding to residues 43, 49, 52, and 53 of the PDGF B chain. 28. The method according to claim 25, 26, or 27, further comprising one or more amino acid substitutions of cysteine residues corresponding to residues 43, 49, 52, and 53 of the PDGF B chain. 29. The method of claim 21 wherein said protein is present in a concentration of from about 1 to 50 micrograms per milliliter of total volume. 30. The method of claim 21 wherein said carrier or diluent is selected from the group consisting of albumin, sterile water, and saline. 31. The method of claim 21 wherein said protein and physiologically acceptable carrier or diluent is administered topically. 32. The method of claim 21, including administering an adjuvant. 33. The method of claim 32 wherein said adjuvant is selected from the group consisting of collagen, hyaluronic acid, fibronectin, factor XIII, and antibiotics.

Details for Patent 5,516,896

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2013-05-14